2-CYCLOHEXYL-6-METHOXY-4-(PIPERIDIN-1-YLMETHYL)-2H-PYRAN-3(6H)-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HKRCYQFPKSEEAE-UHFFFAOYSA-N
Smiles	COC1OC(C2CCCCC2)C(=O)C(=C1)CN3CCCCC3
InChI	InChI=1S/C18H29NO3/c1-21-16-12-15(13-19-10-6-3-7-11-19)17(20)18(22-16)14-8-4-2-5-9-14/h12,14,16,18H,2-11,13H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H29NO3
Molecular Weight	307.43
AlogP	3.34
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	38.77
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	22.0

Assay Description	Organism	Bioactivity
Miticidal activity against Tetranychus urticae (two-spotted spider mite) in kidney beans assessed as mortality under greenhouse at 100 ppm at 25 +/- 2 degC measured after 48 hr of spray	Tetranychus urticae	68.0 %
Miticidal activity against Tetranychus urticae (two-spotted spider mite) in kidney beans assessed as mortality under greenhouse at 300 ppm at 25 +/- 2 degC measured after 48 hr of spray	Tetranychus urticae	100.0 %
Miticidal activity against Tetranychus urticae (two-spotted spider mite) in kidney beans assessed as mortality under greenhouse at 600 ppm at 25 +/- 2 degC measured after 48 hr of spray	Tetranychus urticae	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2287898
PubChem	76327396

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).